Does EVOLOCUMAB Cause Interstitial lung disease? 21 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 21 reports of Interstitial lung disease have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.0% of all adverse event reports for EVOLOCUMAB.
21
Reports of Interstitial lung disease with EVOLOCUMAB
0.0%
of all EVOLOCUMAB reports
2
Deaths
15
Hospitalizations
How Dangerous Is Interstitial lung disease From EVOLOCUMAB?
Of the 21 reports, 2 (9.5%) resulted in death, 15 (71.4%) required hospitalization, and 1 (4.8%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 21 reports have been filed with the FAERS database.
What Other Side Effects Does EVOLOCUMAB Cause?
Device difficult to use (31,807)
Drug dose omission by device (23,957)
Wrong technique in product usage process (21,664)
Accidental exposure to product (16,160)
Injection site pain (9,988)
Product storage error (6,606)
Back pain (5,254)
Myalgia (5,061)
Drug dose omission (4,914)
Injection site bruising (4,409)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which EVOLOCUMAB Alternatives Have Lower Interstitial lung disease Risk?
EVOLOCUMAB vs EXELON
EVOLOCUMAB vs EXEMESTANE
EVOLOCUMAB vs EXENATIDE
EVOLOCUMAB vs EXFORGE
EVOLOCUMAB vs EXJADE